Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Bought by Palumbo Wealth Management LLC

Palumbo Wealth Management LLC raised its position in Inozyme Pharma, Inc. (NASDAQ:INZY) by 52.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 23,281 shares of the company’s stock after acquiring an additional 7,995 shares during the quarter. Palumbo Wealth Management LLC’s holdings in Inozyme Pharma were worth $64,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in Inozyme Pharma in the 3rd quarter worth about $64,000. China Universal Asset Management Co. Ltd. acquired a new stake in Inozyme Pharma in the 4th quarter worth about $38,000. SG Americas Securities LLC acquired a new stake in Inozyme Pharma in the 3rd quarter worth about $81,000. Readystate Asset Management LP purchased a new position in Inozyme Pharma in the 3rd quarter worth approximately $100,000. Finally, OneDigital Investment Advisors LLC lifted its stake in Inozyme Pharma by 51.5% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 20,000 shares of the company’s stock worth $105,000 after purchasing an additional 6,800 shares in the last quarter. 88.30% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Piper Sandler decreased their target price on shares of Inozyme Pharma from $43.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Wedbush reissued an “outperform” rating and issued a $12.00 target price on shares of Inozyme Pharma in a research note on Friday, January 10th. HC Wainwright raised their target price on shares of Inozyme Pharma from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price on shares of Inozyme Pharma in a research note on Wednesday, November 6th. Finally, Wells Fargo & Company decreased their target price on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $18.33.

Inozyme Pharma Stock Up 1.5 %

Shares of NASDAQ INZY opened at $1.37 on Monday. The firm has a market cap of $88.01 million, a price-to-earnings ratio of -0.88 and a beta of 1.29. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. Inozyme Pharma, Inc. has a 52-week low of $1.24 and a 52-week high of $7.80. The business’s 50 day moving average is $2.14 and its two-hundred day moving average is $3.72.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.